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ABSTRACT 
Multimerin 1 (MMRN1) is a massive, homopolymeric protein that is stored in platelets and 
endothelial cells for activation-induced release. In vitro, MMRN1 binds to the outer surfaces of 
activated platelets and endothelial cells, the extracellular matrix (including collagen) and von 
Willebrand factor (VWF) to support platelet adhesive functions. VWF associates with MMRN1 at 
high shear, not static conditions, suggesting that shear exposes cryptic sites within VWF that 
support MMRN1 binding. Modified ELISA and surface plasmon resonance were used to study the 
structural features of VWF that support MMRN1 binding, and determine the affinities for VWF-
MMRN1 binding. High shear microfluidic platelet adhesion assays determined the functional 
consequences for VWF-MMRN1 binding. VWF binding to MMRN1 was enhanced by shear 
exposure and ristocetin, and required VWF A1A2A3 region, specifically the A1 and A3 domains. 
VWF A1A2A3 bound to MMRN1 with a physiologically relevant binding affinity (2.0 ± 0.4 nM), 
whereas the individual VWF A1 (KD: 39.3 ± 7.7 nM) and A3 domains (KD: 229 ± 114 nM) bound 
to MMRN1 with lower affinities. VWF A1A2A3 was also sufficient to support the adhesion of 
resting platelets to MMRN1 at high shear, by a mechanism dependent on VWF-GPIb binding. 
Our study provides new information on the molecular basis of MMRN1 binding to VWF, and its 
role in supporting platelet adhesion at high shear. We propose that at sites of vessel injury, 
MMRN1 that is released following activation of platelets and endothelial cells, binds to VWF 
A1A2A3 region to support platelet adhesion at arterial shear rates. 
 
 
 
KEYWORDS: von Willebrand factor; Platelet glycoproteins; Adhesion molecules; Collagens 
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INTRODUCTION 
 von Willebrand factor (VWF) is a massive, shear-sensitive, homopolymeric protein that is 
important for initiating platelet adhesion at high shear (1). VWF normally circulates in a globular 
form that unfolds, elongates and self-associates in response to high hydrodynamic shear (1-4). 
Shear-exposed VWF reveals multiple cryptic binding sites that support VWF binding to platelet 
glycoprotein (GP) Ib (5-8) and platelet aggregation (9). The exposure of VWF to high shear also 
controls interactions with haemostatic ligands that modulate its platelet adhesive properties, 
including binding to the adhesive protein multimerin 1 (abbreviation: human: MMRN1, mouse: 
Mmrn1) (10). MMRN1 is a massive, variably-sized, disulfide-linked, EMILIN homopolymeric 
protein that is proposed to support platelet function at sites of vessel injury (10-14). 
MMRN1 and VWF have interesting similarities, although they are structurally distinct 
proteins (10, 11, 13). Both MMRN1 and VWF are expressed and stored by megakaryocytes, 
platelets and endothelial cells for stimulus-induced release, but unlike VWF, MMRN1 is not 
normally detectable in plasma (13, 15, 16). VWF and MMRN1 respectively are the main binding 
proteins for the homologous coagulation factors factor VIII (17) and factor V (FV) (18), and 
similarly interact with the phospholipid binding domains of these cofactors to modulate 
coagulation (19, 20). Like VWF, MMRN1 has roles in supporting platelet adhesive functions (10, 
14, 21). Mice with spontaneous deletion of the Mmrn1 and α-synuclein (Snca) gene have both 
defective platelet adhesion and platelet-rich thrombus formation in arterioles injured with ferric 
chloride (14). Additionally, these mice have impaired platelet adhesion to collagen at a high shear 
rate (1500 s-1) that is corrected by added MMRN1 (14). Like VWF, MMRN1 binds to collagens 
types I and III, and VWF and MMRN1 together enhance platelet adhesion to collagen at a high 
shear rate (10). MMRN1 also supports platelet adhesion at low shear rates (e.g., 150 s-1) by 
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mechanisms that require GPIb but not VWF, whereas at a high shear rate, MMRN1 supports 
platelet adhesion by a mechanism that requires both GPIb and VWF (10). VWF associates with 
MMRN1 under high shear rates, but not under static conditions (10), suggesting that high shear 
exposes cryptic sites within VWF that are involved in MMRN1 binding. MMRN1 does not 
detectably bind to GPIb (10), suggesting that VWF binding to MMRN1 and to GPIb supports 
platelet adhesion to MMRN1 at high shear. Nonetheless, the mechanism underlying VWF 
interactions with MMRN1 has not been directly evaluated. 
The shear-sensitive A1A2A3 region of VWF is important for platelet adhesion because 
this region contains the binding sites for GPIb (7, 22), subendothelial collagens (types I, III, IV, 
and VI) (23-27), and the plasma protease ADAMTS13 (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13) (28). In response to vascular injury, the structurally 
homologous VWF A1 and A3 domains bind to subendothelial collagens (23-27), and this 
association enhances exposure of the cryptic A1 domain binding site for GPIb (1, 4, 8, 29, 30). 
VWF A1 domain also possesses binding sites for non-physiological modulators of VWF-GPIb 
binding, such as ristocetin, that also expose cryptic sites within VWF A1 domain (22, 31). VWF 
A2 domain possesses unique structural features that regulate its response to high shear and 
proteolysis by ADAMTS13, which downregulates the platelet-adhesive properties of VWF by 
cleaving it into smaller polymers (1, 28, 32, 33). Like full length VWF, VWF A1A2A3 domains 
respond to high shear (6, 34, 35) and support platelet adhesion at high shear by GPIb-dependent 
mechanisms (6, 34, 36). As VWF A1A2A3 domains have been used to probe the mechanism and 
affinity of VWF binding to other proteins (34, 36, 37), we postulated that these domains would be 
helpful to investigate the mechanism of VWF-MMRN1 binding. 
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The apparent shear-dependent binding of VWF to MMRN1 led us to postulate that the 
shear-sensitive A1A2A3 region of VWF (which is critical for GPIb-dependent platelet adhesion 
(7, 22)) is required for MMRN1 binding and platelet adhesion to MMRN1 at high shear. We tested 
these possibilities using domain-deleted VWF mutant proteins lacking one or more VWF A 
domains, and monomeric VWF mutant proteins possessing one or more A domain(s). 
 
MATERIAL AND METHODS  
 This study was performed with institutional ethics review board approval, in accordance 
with the revised Helsinki Declaration on human research. For platelet adhesion experiments, blood 
was collected with informed consent from 2 or 3 healthy individuals and from an individual with 
type 3 von Willebrand disease (VWD) with undetectable plasma and platelet VWF. 
 
Protein preparation and sources 
 Affinity purified recombinant MMRN1 was prepared as described (21) for protein binding 
and platelet adhesion assays. Biotin-labelled MMRN1 was prepared and immobilized as described 
(20) to assess the binding affinities of VWF A domains for MMRN1 by surface plasmon resonance 
(SPR). Bovine serum albumin (BSA; Sigma-Aldrich Canada, Oakville, ON, Canada) was used as 
the negative control for binding and adhesion assays. 
 VWF mutant proteins tested for MMRN1 binding included: full-length wild-type (WT)-
VWF; VWF lacking the A1A2A3 domains (A1A2A3) (38); and VWF lacking individual A 
domains (A1, A2, A3) (22, 23, 28). The concentrations of VWF mutant proteins were 
determined by an enzyme-linked immunosorbent assay (ELISA), as described (22), using a 
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horseradish peroxidase conjugated, rabbit polyclonal antibody (P0226, Dako, Glostrup, Denmark) 
to detect VWF and mutant VWF proteins lacking one or more A domains.  
Monomeric VWF mutant proteins tested for MMRN1 binding included: A1A2A3, A1, A2, 
and A3 (A2 domain was provided by Dr. E. Huizinga (39-42)). Concentrations of these mutant 
proteins were determined by bicinchoninic acid (BCA) assay (Thermo Scientific, Waltham, MA, 
U.S.A). 
 Triple-helical type III collagen peptides, tested as inhibitors of MMRN1-VWF binding 
included: the collagen peptides  
(III-23: GPC-(GPP)5-GPOGPSGPRGQOGVMGFOGPKGNDGAO-(GPP)5-GPC-NH2 and a 
smaller peptide designated GPRGQOGVMGFO, of full sequence GPC-(GPP)5-
GPRGQOGVMGFO-(GPP)5-GPC-NH2 that specifically bind to VWF A3 domain (43). The 
control peptide (GPP: GPC-(GPP)10-GPC-NH2), that does not bind VWF (43), served as a negative 
control. All of these collagen peptides were verified not to bind to MMRN1 (data not shown).   
 
VWF-MMRN1 binding assays 
 Modified ELISA (10) were used to assess the ability of immobilized MMRN1 (0.5 g per 
well) to support the binding of VWF (0 – 0.2 g per well) that was untreated, pre-treated with 
ristocetin (1 mg/ml), or exposed to shear on a mini vortex mixer for 20-30 sec (2500 – 3200 rpm; 
VWR, Radnor, PA, U.S.A.) as described (44). For other assays, the binding of VWF A1A2A3 (0 
– 0.3 g per well) to MMRN1 was assessed. For some experiments, VWF binding to MMRN1 
was assessed with or without simultaneous addition of the VWF binding collagen peptides III-23, 
GPRGQOGVMGFO, or control peptide GPP (each peptide was tested at 250 g/ml, without 
preincubation with VWF). For other experiments, VWF binding to MMRN1 was assessed with or 
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without simultaneous addition of 2 g/ml control mouse immunoglobulin G (mIgG; Jackson 
ImmunoResearch, West Grove, PA, U.S.A.) or 2 g/ml of an inhibitory monoclonal antibody 
against VWF A1 (MCA4683; AbD Serotec, Raleigh, NC, U.S.A.) or A3 domain (RU5) (43); both 
inhibitory antibodies were assessed at a concentration that inhibits VWF binding to GPIb and 
collagen, respectively (43).   
For binding assays, VWF A1A2A3 mutant proteins were diluted in HEPES-Tyrode buffer 
(137 mM NaCl, 2 mM KCl, 0.3 mM NaH2PO4,1 mM MgCl2, 5 mM HEPES, 12 mM NaHCO3, pH 
7.4), supplemented with 2mM CaCl2. VWF mutant proteins bound to MMRN1 were detected 
using P0226 and the chromogenic substrate tetramethylbenzidine (TMB) (ALerCHEK, Inc. 
ColorburstTM Blue, Portland, ME, USA); reactions were stopped by adding 1 M H2SO4, and 
relative binding was reported as optical density (O.D.) measured at 450 nm (10). Binding assays 
were done three times with each sample, tested in duplicate or triplicate. 
 SPR was performed to assess the binding affinity of VWF A1A2A3 for MMRN1 and the 
binding of individual A domains to MMRN1 because ELISA using P0226 showed inconsistent 
binding of these domains to immobilized MMRN1. Real-time association and dissociation data 
were obtained using BIAcoreX instrument (BIAcore, Uppsala, Sweden). For the evaluation of 
VWF A1A2A3 binding to MMRN1, SPR experiments were conducted using different contact 
times (2 – 10 minutes) and injection flow rates (10 – 40 L/min) to avoid mass transfer effects.  
For kinetic estimates, VWF A domains (in HEPES-Tyrode running buffer, with 0.005% P-
20) were perfused over biotin-labelled MMRN1 (immobilized on streptavidin-coated sensor 
chips).  VWF mutant proteins were tested at concentrations of 0-2000 nM, and those that are 
known to self-aggregate at concentrations above 500 nM (49) were tested at lower concentrations 
(≤ 250 nM for A1, ≤ 25 nM for A1A2A3).  The baseline surface was restored by 1 M NaCl 
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containing 50 mM NaOH, as described (20). Binding affinities were determined using 
BIAEvaluation software (version 4.1) and best-fit models for data (determined by visual inspection 
and Chi2 values), as described (20). For VWF A1A2A3 and VWF A1, the two state conformational 
model was used: KD = (kd1∙kd2)/ka1(kd2+ka2). For VWF A3, the 1:1 Langmuir binding model was 
used: KD = kd/ka (20).  SPR experiments were repeated two or more times for each analyte, using 
different MMRN1 preparations, with immobilization levels ranging from 500 – 1000 resonance 
units (RU). 
 
Platelet preparation and microfluidic platelet adhesion assays 
 Blood was collected into low molecular weight heparin anticoagulant (final: 20 U/ml 
dalteparin sodium, Pfizer Canada Inc., Mississauga, ON, Canada) to prepare calcein-labelled, 
washed platelets for adhesion assays, as described (10). After collecting platelet-rich plasma, 
platelets were incubated with calcein acetoxymethyl ester (2.5 g/ml; Invitrogen Canada Inc., 
Burlington, ON, Canada), followed by washing and resuspension in HEPES-Tyrode buffer with 
added red cells (final: 300 x 106 platelets/ml; haematocrit 45%) (10).   
High shear (1500s-1) platelet adhesion assays were performed to determine if VWF 
A1A2A3 supported platelet adhesion to MMRN1. Briefly, Vena8Fluoro+ Biochips (Cellix, 
Dublin, Ireland) were coated with MMRN1 or BSA (50 g/ml overnight, 4°C), then blocked with 
2% BSA in HEPES-Tyrode buffer for 2 hours at room temperatures before use. Protein-coated 
chambers were then pre-treated with VWF A1A2A3 (40 nM, estimated based on a 72.5 kDa 
monomer size), WT-VWF (40 nM, positive control; estimated based on a 250 kDa monomer size), 
or 0.2% BSA (negative control) in HEPES-Tyrode buffer, by flowing these proteins over the 
surfaces at high shear (1500s-1, 6 min) using Mirus™ 2.0 Nanopump (Cellix, Dublin, Ireland) and 
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VenaFluxAssay™ Software (Cellix, Dublin, Ireland). Next, labelled platelets in reconstituted 
blood were drawn through the chambers at high shear (1500 s-1, 3 min), followed by a wash step 
(0.2% BSA in HEPES-Tyrode supplemented with 1 U/ml heparin) before endpoint analysis of 
adherent platelets (% area covered by platelets) by microscopy, as described (10). For some 
experiments, MMRN1-coated chambers were perfused with WT-VWF, with or without 
simultaneously added 20 g/ml of control mouse IgG or MCA4683 (inhibitory antibody against 
VWF A1).  Platelet adhesion assays were conducted at least two times with different protein 
preparations. 
  
Statistical analysis  
 Data were reported as mean (minus background) ± standard error of the mean (SEM) unless 
otherwise stated. Comparative data with two groups were evaluated by an unpaired two-tailed 
Student’s t test. Comparative data with three or more groups were evaluated by one-way analysis 
of variance (ANOVA) followed by Tukey multiple comparisons post hoc test (GraphPad Prism 5, 
La Jolla, CA, USA). p values < 0.05 were considered statistically significant.  
 
RESULTS 
Static binding of WT-VWF and VWF A domains mutant proteins to MMRN1 
In modified ELISA, WT-VWF bound to immobilized MMRN1 in a concentration-
dependent and saturable manner when exposed to ristocetin or shear (Figure 1A). The binding of 
ristocetin and shear exposed WT-VWF exceeded the binding of untreated VWF to MMRN1 (p < 
0.05, Figure 1A), which was not detectable in some experiments. VWF A1A2A3 (tested without 
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exposure to shear or ristocetin) also showed saturable, concentration-dependent binding to 
MMRN1 in modified ELISA (p < 0.01 relative to BSA; Figure 1B).  
The contributions of VWF A domains to MMRN1 binding was further evaluated with shear 
exposed, domain deleted VWF mutant proteins. Compared to WT-VWF, VWF mutant proteins 
lacking all A domains (A1A2A3) showed impaired binding to MMRN1 (p < 0.01), as did VWF 
mutant proteins lacking the A1 (A1) or A3 (A3) domains (p < 0.01), but not the VWF mutant 
lacking the A2 domain (A2; Figure 2A). A1A2A3, A1, and A3 VWF mutant proteins had 
binding that was reduced to the level of background (Figure 2A). WT-VWF binding to 
immobilized MMRN1 in modified ELISA was reduced by monoclonal antibodies that inhibit the 
VWF A1 (~55% reduction; MCA4683; p<0.05, relative to VWF alone, Figure 2B) and A3 (~55% 
reduction; RU5; p < 0.05, relative to VWF alone; Figure 2C) domains, and by the type III collagen 
peptides III-23 and smaller peptide, GPRGQOGVMGFO (~70% reduction; p < 0.01, relative to 
no added peptide; Figure 2D). Both collagen peptides that showed inhibitory effects are known to 
bind VWF A3 domain and inhibit VWF A3 binding to collagen type III at the concentration tested 
(43). The negative controls, collagen peptide GPP and mIgG, had no effect on WT-VWF binding 
to immobilized MMRN1 (Figure 2B-D). The effect of collagen peptides on VWF-MMRN1 
binding could not be evaluated by SPR because the peptides showed a high level of non-specific 
binding to the sensorchips. 
 
The effect of inhibitory antibody against VWF A1-GPIb binding, on platelet adhesion to 
MMRN1 at high shear (1500 s-1) 
MMRN1 surfaces treated with VWF supported the adhesion of resting control platelets 
better than MMRN1 surfaces pre-treated with BSA (p < 0.001) and this enhancing effect of VWF 
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was abrogated by the inhibitory antibody MCA4683 that blocks VWF A1-GPIb binding (p < 
0.001 relative to WT-VWF alone) but not by control mIgG (Figure 3).  
 
SPR analysis of the binding of VWF A domains to MMRN1 
 SPR analysis indicated that VWF A1, A3, and A1A2A3 domains bound to MMRN1, unlike 
the VWF A2 domain (Figure 4A). VWF A3 domain showed slower association and dissociation 
from MMRN1 than the A1 domain (Figure 4A). VWF A1A2A3 binding to MMRN1 showed some 
features of VWF A1 domain and A3 domain binding to MMRN1 (Figure 4A). Like VWF A1 
domain, VWF A1A2A3 showed rapid initial association to MMRN1, followed by a slower gradual 
association that was also observed with the VWF A3 domain (Figure 4A). Like VWF A1 domain, 
VWF A1A2A3 showed an initial rapid dissociation from MMRN1, that was followed by a second 
slower phase of dissociation that resembled dissociation of the VWF A3 domain from MMRN1 
and the later phase of VWF A1 domain dissociation from MMRN1 (Figure 4A). 
 Table 1 summarizes the binding kinetic estimations for the real-time binding of VWF 
A1A2A3, A1, and A3 domains to MMRN1. In agreement with the association and dissociation 
profiles, the binding of VWF A1A2A3 and the A1 domain to MMRN1 showed best fit (Chi2: 2.32 
- 9.34) to a two-state, conformational change binding model (A+L ↔AL ↔AL*), where A 
(analyte: A1A2A3 or A1) and L (Ligand: MMRN1) form two stable complexes (AL and AL*). 
The binding of VWF A3 domain to MMRN1 showed best fit (Chi2: 1.07 – 3.19) to a simple 1:1 
Langmuir binding model (A+L ↔AL), unlike VWF A1A2A3 (Chi2 ≥ 30). 
 Using the two state conformational model, VWF A1A2A3 had a lower KD (representative 
of higher apparent affinity) for MMRN1 (KD: 2.0 ± 0.4 x 10
-9 M; Figure 4B) than the VWF A1 
domain (KD: 39.3 ± 7.7 x 10
-9 M, p < 0.01; Figure 4C). VWF A1A2A3 (ka1: 2.6 ± 0.9 x 10
6 M-1s-
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1; ka2: 4.2 ± 0.3 x 10
-3 s-1) and VWF A1 (ka1: 1.2 ± 0.8 x 10
6 M-1s-1; ka2: 1.0 ± 0.5 x 10
-2 s-1) had 
similar on-rates for binding MMRN1 (p = 0.35 and 0.28 respectively). VWF A1A2A3 had a slower 
initial off-rate (kd1: 2.7 ± 0.3 x 10
-2 s-1) than the A1 domain (kd1: 1.3 ± 0.2 x 10
-1 s-1, p < 0.01). A 
second slower phase of the dissociation was evident with both VWF A1A2A3 and the A1 domain 
(kd2: 1.1 ± 0.5 x 10
-3 s-1 vs kd2: 3.2 ± 2.1 x 10
-3 s-1 respectively) (p = 0.31). 
 Compared to VWF A1A2A3, VWF A3 bound to MMRN1 with a higher KD (representative 
of lower affinity; KD: 2.0 ± 0.4 vs 229 ± 114 x 10
-9 M respectively) (p < 0.05; Figure 4D). VWF 
A3 binding to MMRN1 had slow on-rates (ka: 8.8 ± 2.1 x 10
3 M-1s-1) and slow off-rates (kd: 1.8 ± 
0.5 x 10-3 s-1).  
 
The effect of VWF A1A2A3 on platelet adhesion to MMRN1 at high shear (1500 s-1) 
 MMRN1 surfaces pre-treated with WT-VWF or VWF A1A2A3 (40 nM) supported the 
adhesion of resting platelets from controls and a type 3 VWD subject better than MMRN1 surfaces 
pre-treated with BSA (p < 0.001, Figure 5). Control BSA surfaces, similarly pre-treated with VWF 
A1A2A3, supported ≤ 5% of the platelet adhesion observed with MMRN1 surfaces (Figure 5B). 
 
DISCUSSION 
 Roles are emerging for MMRN1 in supporting VWF-dependent platelet adhesion at high 
shear, a process that requires VWF to associate with MMRN1 to support GPIb-dependent platelet 
adhesion (10). The goal of this study was to define the structural features of VWF that support 
MMRN1 binding and platelet adhesion to MMRN1 at high shear, and determine the affinities of 
VWF-MMRN1 binding using VWF A domain mutant proteins. We tested the hypothesis that 
VWF-MMRN1 binding, which is enhanced by exposing VWF to high shear rates (Figure 1A), 
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involves the shear-sensitive A1A2A3 domains of VWF (Figure 1B and 4). We identified the A1 
and A3 domains of VWF as specifically important for VWF binding to MMRN1 (Figure 2 and 4). 
VWF A2 domain did not bind to MMRN1 (Figure 2 and 4A). The entire VWF A1A2A3 region 
showed higher affinity for MMRN1 (2.0 ± 0.4 x 10-9 M) than the individual VWF A1 (KD: 39.3 ± 
7.7 x 10-9 M) and A3 domains (KD: 229 ± 114 x 10
-9 M). Additionally, like WT-VWF exposed to 
high shear or ristocetin (Figure 1A), VWF A1A2A3 bound to MMRN1 and resting platelets at 
high shear, and supported high shear platelet adhesion to MMRN1 (Figure 1B and 5). The affinity 
and nature of VWF-MMRN1 binding suggests that at sites of vessel injury, where MMRN1 is 
released from activated platelets and endothelium (12, 13, 15, 16, 45), VWF binding to MMRN1 
occurs and facilitates GPIb-dependent platelet adhesion at high shear (10). Our study extends the 
known functions of the VWF A domains to MMRN1 binding.  
Shear-induced activation of VWF (or VWF activation by the agonist ristocetin (31)) 
reveals the cryptic GPIb binding site in VWF A1 domain (6, 29); similarly, shear and ristocetin 
revealed MMRN1 binding sites in VWF (Figure 1A). VWF A1A2A3 domain mutant protein 
bound to MMRN1 without shear or ristocetin, possibly because cryptic binding sites are more 
exposed in this mutant protein than in the full-length molecule. Our observation that the VWF A1 
domain is important for MMRN1 binding suggests that there is potential overlap in the binding 
sites of GPIb and MMRN1 within VWF A1 domain (Figure 2, 3 and 4). However, MMRN1 
likely does not impair GPIb binding to VWF, as A1A2A3-loaded MMRN1 matrices supported 
platelet adhesion at a high shear rate (Figure 5), demonstrating that VWF A1A2A3 bound to 
MMRN1 retains its ability to bind to platelet GPIb. MMRN1 has not been shown to bind GPIb 
directly (10), and the observations that MCA4683 (inhibitor of VWF-GPIb binding) completely 
inhibited platelet adhesion to MMRN1 at high shear (Figure 3), further emphasizes that VWF-
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GPIb binding is essential for platelet adhesion to MMRN1 at high shear. MMRN1 binding to 
VWF A1 domain parallels the observations made on VWF A domain binding to subendothelial 
collagens (23-27). MMRN1 is a normal constituent of the vascular extracellular matrix (16), and 
it may enhance VWF binding at sites of vascular damage, like laminin and fibronectin, which also 
bind VWF and support GPIb-dependent platelet adhesion (46, 47).  
VWF A3 domain, which is structurally homologous to VWF A1 domain, was also 
important for MMRN1 binding (Figure 2). RU5 and type III collagen peptides that specifically 
bind to VWF A3 domain, and inhibit collagen binding (43), partially inhibited the binding of VWF 
to MMRN1 (Figure 2C-D). This suggests that there may be overlap in the binding sites for type 
III collagen and MMRN1 within VWF A3 domain. Overlap in VWF A3 binding sites for matrix 
ligands, such as MMRN1 and type III collagen, might provide a redundant mechanism to optimize 
the capture of VWF at sites of vessel injury, as also postulated for laminin and fibronectin (46, 
47).  
In the current study, we used VWF A1A2A3 domains to assess the mechanism and affinity 
of VWF-MMRN1 binding, as previously we found inconsistent binding of WT-VWF to MMRN1 
by SPR (10). Furthermore, the highly polymeric nature of both VWF and MMRN1 challenges the 
estimation of affinity because the combined strength of multiple bonds (instead of a single bond) 
results in measurements of avidity. We were successful in obtaining affinity estimates using 
monomeric VWF A1A2A3 (Table 1). VWF A1A2A3 bound to MMRN1 with high, 
physiologically relevant affinity (KD: 2.0 ± 0.4 x 10
-9 M), that is well below VWF plasma levels 
(~40  x 10-9 M), unlike the modest binding of individual VWF A1 and A3 domains (KD: 39.3 ± 7.7 
x 10-9 M and 229 ± 114 x 10-9 M, respectively). Interestingly, the binding of A1A2A3 domain, and 
the A1 domain, to MMRN1 showed best fit with a two-step, conformational change model, which 
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we reported for factor V, but not factor Va binding to MMRN1 (20). It is possible that in the case 
of VWF binding to MMRN1, the change in conformation might be in the VWF A domains, 
MMRN1 or both. Our estimate of the affinity of VWF A1A2A3 for MMRN1 suggests that at sites 
of arterial vascular injury, where VWF undergoes shear-induced activation (1), released MMRN1 
binds to plasma VWF to further support platelet adhesion. The data that we obtained by testing 
individual A domains of VWF, inhibitory antibodies and deletion mutant proteins suggest that 
multiple VWF A domains contribute to MMRN1 binding, with the main binding site for MMRN1 
located within the VWF A1 domain. However, we cannot exclude the possibility that the low 
binding affinity that was seen with the VWF A3 domain was an artefact of an altered conformation 
induced by absence of the neighbouring N and C terminal domains. It is also possible that the 
multimeric structure of WT-VWF enhances the binding of VWF A3 domain to MMRN1, as it 
influences VWF A3 binding to collagen (39, 48). VWF is known to self-associate at high 
concentrations (> 500 nM) (49), and this is mediated by interactions with VWF A1 and A2 
domains, as well as neighbouring N- and C- terminal domains, but does not require the A3 domain 
(2, 50). Based on the concentrations of VWF mutant proteins that we tested, we suspect that there 
was minimal interference from self-association of mutant proteins in our kinetic estimations, 
particularly for A1A2A3. It is important to note that VWF A domain mutant proteins typically 
underestimate WT-VWF binding affinities by several orders of magnitude because neighbouring 
functional domains alter VWF binding affinities and avidities (37, 43). Similarly, we likely 
underestimated the affinity of WT-VWF for MMRN1 by studying the binding of VWF A1A2A3 
to MMRN1. 
VWD is a heterogeneous disease characterized by defects in VWF quantity (types 1 and 3) 
and quality/functionality (type 2). Type 2M VWD is the disease subgroup defined by several 
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mutations within VWF A1A2A3 domains that abrogate VWF A1 binding to GPIb, and the 
binding of the VWF A1 and A3 domains to collagens (1, 27, 48). The data presented here describes 
MMRN1 as a novel ligand for VWF A1A2A3 region, and suggests that impaired VWF binding to 
MMRN1 could occur in some forms of VWD, reducing VWF-GPIb-dependent platelet adhesion 
at sites of vessel injury. 
 Our study provides new information on the molecular basis of MMRN1 binding to VWF, 
which supports platelet adhesion at high shear (10). We propose that at sites of vessel injury, where 
MMRN1 is released from the storage granules of platelets and endothelial cells (12, 13, 15, 16, 
45), MMRN1 binds to VWF A1A2A3 region and other components of the extracellular matrix 
(including collagen), to support platelet adhesion at arterial shear rates (10, 16, 21). Gene knockout 
animal models provide important insights on many protein functions (14), so we are now 
characterizing multimerin 1 functions in vivo using mice with a selective deficiency. 
 
ACKNOWLEDGMENTS:  
We thank E.G. Huizinga for providing us with VWF A2 domain, Lisa A. Westfield for providing 
support on working with VWF plasmids, and Nola Fuller for providing guidance with SPR. This 
work was supported by Canadian Health Institute Research grant MOP 133474 (CPMH), Heart 
and Stroke Foundation of Ontario grant T6586 (CPMH), British Heart Foundation 
(RG/09/003/27122) and the Wellcome Trust (094470/Z/10/Z) grants to RWF, and National 
Institutes of Health grants HL072917 and HL112303 (JES).  
 
REFERENCES 
VWF A1A2A3 domains support MMRN1 binding 
Page 17 of 32 
 
1. Springer TA. von Willebrand factor, Jedi knight of the bloodstream. Blood 2014; 124: 
1412-1425. 
2. Savage B, Sixma JJ, Ruggeri ZM. Functional self-association of von Willebrand factor 
during platelet adhesion under flow. Proc Natl Acad Sci USA 2002; 99: 425-430. 
3. De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor 
strings puzzle. Blood 2013; 121: 270-277. 
4. Colace TV, Diamond SL. Direct observation of von Willebrand factor elongation and fiber 
formation on collagen during acute whole blood exposure to pathological flow. Arterioscler 
Thromb Vasc Biol 2013; 33: 105-113. 
5. Dayananda KM, Singh I, Mondal N, et al. von Willebrand factor self-association on platelet 
GpIbalpha under hydrodynamic shear: effect on shear-induced platelet activation. Blood 2010; 
116: 3990-3998. 
6. Auton M, Sowa KE, Smith SM, et al. Destabilization of the A1 domain in von Willebrand 
factor dissociates the A1A2A3 tri-domain and provokes spontaneous binding to glycoprotein 
Ibalpha and platelet activation under shear stress. J Biol Chem 2010; 285: 22831-22839. 
7. Cruz MA, Diacovo TG, Emsley J, et al. Mapping the glycoprotein Ib-binding site in the 
von willebrand factor A1 domain. J Biol Chem 2000; 275: 19098-19105. 
8. Emsley J, Cruz M, Handin R, et al. Crystal structure of the von Willebrand Factor A1 
domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem 1998; 273: 10396-
10401. 
9. Peterson DM, Stathopoulos NA, Giorgio TD, et al. Shear-induced platelet aggregation 
requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood 1987; 
69: 625-628. 
VWF A1A2A3 domains support MMRN1 binding 
Page 18 of 32 
 
10. Tasneem S, Adam F, Minullina I, et al. Platelet adhesion to multimerin 1 in vitro: 
influences of platelet membrane receptors, von Willebrand factor and shear. J Thromb Haemost  
2009; 7: 685-692. 
11. Hayward CP, Hassell JA, Denomme GA, et al. The cDNA sequence of human endothelial 
cell multimerin. A unique protein with RGDS, coiled-coil, and epidermal growth factor-like 
domains and a carboxyl terminus similar to the globular domain of complement C1q and collagens 
type VIII and X. J Biol Chem 1995; 270: 18246-18251. 
12. Hayward CP, Warkentin TE, Horsewood P, et al. Multimerin: a series of large disulfide-
linked multimeric proteins within platelets. Blood 1991; 77: 2556-2560. 
13. Jeimy SB, Tasneem S, Cramer EM, et al. Multimerin 1. Platelets 2008; 19: 83-95. 
14. Tasneem S, Reheman A, Ni H, et al. Mice with deleted multimerin 1 and alpha-synuclein 
genes have impaired platelet adhesion and impaired thrombus formation that is corrected by 
multimerin 1. Thromb Res 2010; 125: e177-e183. 
15. Hayward CP, Bainton DF, Smith JW, et al. Multimerin is found in the alpha-granules of 
resting platelets and is synthesized by a megakaryocytic cell line. J Clin Invest 1993; 91: 2630-
2639. 
16. Hayward CP, Cramer EM, Song Z, et al. Studies of multimerin in human endothelial cells. 
Blood 1998; 91: 1304-1317. 
17. Yee A, Gildersleeve RD, Gu S, et al. A von Willebrand factor fragment containing the 
D'D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood 2014; 124: 445-452. 
18. Hayward CP, Furmaniak-Kazmierczak E, Cieutat AM, et al. Factor V is complexed with 
multimerin in resting platelet lysates and colocalizes with multimerin in platelet alpha-granules. J 
Biol Chem 1995; 270: 19217-19224. 
VWF A1A2A3 domains support MMRN1 binding 
Page 19 of 32 
 
19. Jeimy SB, Woram RA, Fuller N, et al. Identification of the MMRN1 binding region within 
the C2 domain of human factor V. J Biol Chem 2004; 279: 51466-51471. 
20. Jeimy SB, Fuller N, Tasneem S, et al. Multimerin 1 binds factor V and activated factor V 
with high affinity and inhibits thrombin generation. Thromb Haemost 2008; 100: 1058-1067. 
21. Adam F, Zheng S, Joshi N, et al. Analyses of cellular multimerin 1 receptors: in vitro 
evidence of binding mediated by alphaIIbbeta3 and alphavbeta3. Thromb Haemost 2005; 94: 
1004-1011. 
22. Sixma JJ, Schiphorst ME, Verweij CL, et al. Effect of deletion of the A1 domain of von 
Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur 
J Biochem 1991; 196: 369-375. 
23. Lankhof H, van Hoeij M, Schiphorst ME, et al. A3 domain is essential for interaction of 
von Willebrand factor with collagen type III. Thromb Haemost 1996; 75: 950-958. 
24. Hoylaerts MF, Yamamoto H, Nuyts K, et al. von Willebrand factor binds to native collagen 
VI primarily via its A1 domain. Biochem J 1997; 324: 185-191. 
25. Mazzucato M, Spessotto P, Masotti A, et al. Identification of domains responsible for von 
Willebrand factor type VI collagen interaction mediating platelet adhesion under high flow. J Biol 
Chem 1999; 274: 3033-3041. 
26. Flood VH, Gill JC, Christopherson PA, et al. Critical von Willebrand factor A1 domain 
residues influence type VI collagen binding. J Thromb Haemost 2012; 10: 1417-1424. 
27. Flood VH, Schlauderaff AC, Haberichter SL, et al. Crucial role for the VWF A1 domain 
in binding to type IV collagen. Blood 2015; 125: 2297-2304. 
28. Lankhof H, Damas C, Schiphorst ME, et al. von Willebrand factor without the A2 domain 
is resistant to proteolysis. Thromb Haemost 1997; 77: 1008-1013. 
VWF A1A2A3 domains support MMRN1 binding 
Page 20 of 32 
 
29. Miyata S, Goto S, Federici AB, et al. Conformational changes in the A1 domain of von 
Willebrand factor modulating the interaction with platelet glycoprotein Ibalpha. J Biol Chem 1996; 
271: 9046-9053. 
30. Miyata S, Ruggeri ZM. Distinct structural attributes regulating von Willebrand factor A1 
domain interaction with platelet glycoprotein Ibalpha under flow. J Biol Chem 1999; 274: 6586-
6593. 
31. Dong JF, Berndt MC, Schade A, et al. Ristocetin-dependent, but not botrocetin-dependent, 
binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with 
shear-dependent interactions. Blood 2001; 97: 162-168. 
32. Luken BM, Winn LY, Emsley J, et al. The importance of vicinal cysteines, C1669 and 
C1670, for von Willebrand factor A2 domain function. Blood 2010; 115: 4910-4913. 
33. Zhang Q, Zhou YF, Zhang CZ, et al. Structural specializations of A2, a force-sensing 
domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci USA 2009; 
106: 9226-9231. 
34. Auton M, Sowa KE, Behymer M, et al. N-terminal flanking region of A1 domain in von 
Willebrand factor stabilizes structure of A1A2A3 complex and modulates platelet activation under 
shear stress. J Biol Chem 2012; 287: 14579-14585. 
35. Fu X, Chen J, Gallagher R, et al. Shear stress-induced unfolding of VWF accelerates 
oxidation of key methionine residues in the A1A2A3 region. Blood 2011; 118: 5283-5291. 
36. Da Q, Behymer M, Correa JI, et al. Platelet adhesion involves a novel interaction between 
vimentin and von Willebrand factor under high shear stress. Blood 2014; 123: 2715-2721. 
VWF A1A2A3 domains support MMRN1 binding 
Page 21 of 32 
 
37. Scaglione GL, Lancellotti S, Papi M, et al. The type 2B p.R1306W natural mutation of von 
Willebrand factor dramatically enhances the multimer sensitivity to shear stress. J Thromb 
Haemost 2013; 11: 1688-1698. 
38. Nishio K, Anderson PJ, Zheng XL, et al. Binding of platelet glycoprotein Ibalpha to von 
Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. 
Proc Natl Acad Sci USA 2004; 101: 10578-10583. 
39. Huizinga EG, Martijn vdPR, Kroon J, et al. Crystal structure of the A3 domain of human 
von Willebrand factor: implications for collagen binding. Structure 1997; 5: 1147-1156. 
40. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo 
survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol 
Chem 2004; 279: 12102-12109. 
41. Zhang X, Halvorsen K, Zhang CZ, et al. Mechanoenzymatic cleavage of the ultralarge 
vascular protein von Willebrand factor. Science 2009; 324: 1330-1334. 
42. Hulstein JJ, Lenting PJ, de Laat B, et al. beta2-Glycoprotein I inhibits von Willebrand 
factor dependent platelet adhesion and aggregation. Blood 2007; 110: 1483-1491. 
43. Lisman T, Raynal N, Groeneveld D, et al. A single high-affinity binding site for von 
Willebrand factor in collagen III, identified using synthetic triple-helical peptides. Blood 2006; 
108: 3753-3756. 
44. Zhang P, Pan W, Rux AH, et al. The cooperative activity between the carboxyl-terminal 
TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand 
factor under flow. Blood 2007; 110: 1887-1894. 
45. Hayward CP, Smith JW, Horsewood P, et al. p-155, a multimeric platelet protein that is 
expressed on activated platelets. J Biol Chem 1991; 266: 7114-7120. 
VWF A1A2A3 domains support MMRN1 binding 
Page 22 of 32 
 
46. Beumer S, Heijnen HF, IJsseldijk MJ, et al. Platelet adhesion to fibronectin in flow: the 
importance of von Willebrand factor and glycoprotein Ib. Blood 1995; 86: 3452-3460. 
47. Inoue O, Suzuki-Inoue K, Ozaki Y. Redundant mechanism of platelet adhesion to laminin 
and collagen under flow: involvement of von Willebrand factor and glycoprotein Ib-IX-V. J Biol 
Chem 2008; 283: 16279-16282. 
48. Flood VH, Gill JC, Christopherson PA, et al. Comparison of type I, type III and type VI 
collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost 2012; 10: 
1425-1432 
49. Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating 
shear-induced platelet activation and self-association of von Willebrand factor in suspension. 
Blood 2003; 101: 2637-2645. 
50. Martin C, Morales LD, Cruz MA. Purified A2 domain of von Willebrand factor binds to 
the active conformation of von Willebrand factor and blocks the interaction with platelet 
glycoprotein Ibalpha. J Thromb Haemost 2007; 5: 1363-1370. 
 
  
VWF A1A2A3 domains support MMRN1 binding 
Page 23 of 32 
 
LEGENDS TO FIGURES  
 
Figure 1: VWF-MMRN1 binding, in modified ELISA. A) Binding of untreated (open circles, 
solid line), shear-exposed (closed circles, solid line) and ristocetin-treated (closed circles, dashed 
line) WT-VWF to immobilized MMRN1. * indicates different (p < 0.05) from untreated VWF. B) 
Binding of VWF A1A2A3 to immobilized MMRN1 (closed circles) and the negative control 
protein BSA (open circles). * indicates different (p < 0.01) from BSA. Binding data are 
representative of 2-3 separate experiments, expressed as the mean OD 450 nm ± SD. 
 
Figure 2: Binding of WT-VWF and VWF mutant proteins to immobilized MMRN1, with or 
without inhibitors. A) The binding of 0.5 g/ml shear-exposed WT-VWF, and VWF mutant 
proteins lacking all or one A domain (A1A2A3, A1, A2, A3), to MMRN1. * indicate reduced 
binding (p < 0.01), relative to WT-VWF. B) Effect of MCA4683 (2 g/ml, a VWF A1 domain 
antibody that inhibits GPIb binding) or negative control mIgG (2 g/ml) on VWF-MMRN1 
binding in the presence of ristocetin. * indicates reduced (p < 0.05), relative to WT-VWF with no 
inhibitor. C) Effect of RU5 (2 g/ml, a VWF A3 domain antibody that inhibits collagen binding) 
and mIgG (2 g/ml; negative control) on VWF-MMRN1 binding. * indicates reduced (p < 0.05), 
relative to WT-VWF with no inhibitor. D) Effect of type III collagen peptides that bind to VWF 
A3 domain (III-23: GPOGPSGPRGQOGVMGFOGPKGNDGAO, and GPRGQOGVMGFO) and 
the negative control peptide, GPP, on VWF-MMRN1 binding. * indicates reduced, (p < 0.05), 
relative to WT-VWF with no inhibitor. WT-VWF binding (1 g/ml) to immobilized MMRN1 was 
measured following simultaneous addition of VWF and an antibody or peptide. Panels show 
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representative (D) or pooled (A-C) data for 3 separate independent experiments, expressed as the 
mean OD 450 nm ± SEM. 
 
Figure 3: Effect of inhibitory antibodies on the ability of VWF to support high shear 
platelet adhesion to immobilized MMRN1. Bars show mean ± SEM for the percentage of the 
surface area [%] covered by platelets for the adhesion of control platelets (300 x 106/ml) to 
immobilized MMRN1, tested at a shear rate of 1500 s-1 after pre-treatment with: WT-VWF (40 
nM, positive control); WT-VWF + MCA4683 (20 g/mL, inhibits VWF-GPIb binding); BSA 
(negative control); or WT-VWF + mIgG (20 g/mL, negative control). Reduced platelet 
adhesion to MMRN1 is indicated (*; p < 0.001, relative to MMRN1 pre-treated with WT-VWF 
only; data representative of 2 independent experiments). 
 
Figure 4: Real time association and dissociation curves for VWF A domains binding to 
MMRN1, evaluated by SPR. Panel A shows the association and dissociation profiles for VWF: 
A1A2A3 (25 nM); and A1, A2, and A3 domain (250 nM) binding to MMRN1-coated sensor 
chips (~1000 RU immobilized MMRN1; flow rate: 20 l/min). Panels B, C and D show SPR 
sensorgrams for the real-time binding of different analytes to MMRN1-coated sensor chips (data 
for chips with ~1000 RU immobilized MMRN1 are shown): B) VWF A1A2A3 were tested at 
analyte concentrations (nM, top to bottom): 25, 18.8, 9.4, 4.7 and 3.1; C) VWF A1 domain was 
tested at analyte concentrations (nM, top to bottom) of: 250, 125, 62.5, 31.3 and 15.6; and D) 
VWF A3 domain was tested at analyte concentrations (nM, top to bottom) of: 2000, 1000, 500 
and 250. All data shown was representative of 2-3 experiments. 
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Figure 5: Effect of VWF A1A2A3 on platelet adhesion to MMRN1, under high shear 
(1500s-1). The adhesion (expressed as mean ± SEM for the percentage, %, area covered by 
platelets) of control (CTL) and type 3 VWD platelets (300 x 106/ml) to immobilized MMRN1, 
tested at a shear rate of 1500 s-1 after pre-treatment with: VWF A1A2A3 (40 nM), WT-VWF (40 
nM; positive control) or BSA (negative control). A) Pre-treatments that increased platelet 
adhesion to MMRN1 are indicated (*; p < 0.001, relative to MMRN1 pre-treated with BSA; data 
representative of 3 independent experiments). B) Microscope images (representative of 3 
independent experiments) comparing the adhesion of control (CTL) and type 3 VWD platelets to 
MMRN1 and BSA-coated surfaces that were pre-treated with VWF A1A2A3 (40 nM) or BSA. 
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Table 1: Binding kinetic estimations for the real-time binding between VWF A1A2A3, A1, and 
A3 binding to MMRN1, as measured by SPR.  
VWF 
Analyte 
Binding 
model 
Estimated 
affinity  
Estimated association rate 
constant 
Estimated dissociation 
rate constant 
A1A2A3 2-State 
KD: 2.0 ± 0.4 
x 10-9 M 
ka1: 2.6 ± 0.9 x 10
6 M-1s-1 
ka2: 4.2 ± 0.3 x 10
-3 s-1 
kd1: 2.7 ± 0.3 x 10
-2 s-1 
kd2: 1.1 ± 0.5 x 10
-3 s-1  
A1 2-State  
KD: 39.3 ± 7.7 
x 10-9 M 
ka1: 1.2 ± 0.8 x10
6 M-1s-1 
ka2: 1.0 ± 0.5 x 10
-2  s-1 
kd1: 1.3 ± 0.2 x 10
-1 s-1 
kd2: 3.2 ± 2.1 x 10
-3 s-1  
A3 1:1 Langmuir 
KD: 229 ± 114 
x 10-9 M 
ka: 8.8 ± 2.1 x 10
3 M-1s-1 kd: 1.8 ± 0.5 x 10
-3 s-1 
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EXTRA TABLE  
 
What is known on this topic? 
 
 Activation of endothelial cells and platelets lead to MMRN1 release from 
intracellular stores, and MMRN1 binding to outer cell surfaces 
 VWF associates with MMRN1 matrices at high shear rates 
 MMRN1 supports platelet adhesion at high shear by a VWF-dependent mechanism 
involving GPIb not 3 integrins 
 
What this paper adds? 
 
 VWF-MMRN1 binding is enhanced by exposing VWF to shear or treating VWF 
with ristocetin 
 MMRN1 binds to VWF A1A2A3, and to the individual VWF A1 and A3 domains 
 VWF A1A2A3 binds to MMRN1 with a physiologically relevant binding affinity, 
whereas the individual VWF A1 and A3 domains bind to MMRN1 with low to 
modest affinity 
 VWF A1A2A3 binds to MMRN1 and this region of VWF is sufficient to support 
the GPIb-dependent adhesion of resting platelets to MMRN1, at a high shear rate 
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